secwatch.observer — SEC 8-K summary
======================================

Issuer:     Milestone Pharmaceuticals Inc. (MIST)
CIK:        0001408443
Form:       8-K
Filed at:   2024-09-04T23:59:59+00:00
Accession:  0001104659-24-096648
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Milestone Pharmaceuticals appoints Joseph Papa to Board of Directors
--------------------------------------------------------------------

- Joseph Papa, CEO of Emergent BioSolutions, appointed director effective Sept 3, 2024; over 35 years pharma experience.
- Papa will serve on Compensation Committee; receives $42,500 annual cash retainer and 80,000-share option grant.
- 2024 annual meeting results: all 7 director nominees elected; PricewaterhouseCoopers ratified as auditor.
- Board committees updated: Fischer named Compensation Chair; Papa joins Compensation Committee.
- Company advancing CARDAMYST (etripamil nasal spray) for PSVT towards potential FDA decision.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1408443/000110465924096648/0001104659-24-096648-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1408443/000110465924096648/tm2423263d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-096648

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer